Topikal Retinoidler: Alitretinoin
Özet
Alitretinoin (9-cis-retinoik asit), topikal formülasyonu (%0,1 jel) sınırlı Kaposi sarkomu tedavisinde endike olan bir retinoiddir. Etkisini diğer retinoidlerden farklı olarak tüm retinoik asit reseptörleri ve retinoid X reseptörlerine bağlanarak gösterir. Böylece hem antiproliferatif, apopitotik etki, hem de antiinflamatuvar ve immünmodülatuvar etkiye sahiptir. Kaposi sarkomu tedavisi yanında deri yaşlanması ve piyojenik granülom tedavisindede kullanılmış ve etkili bulunmuştur. Diğer retinoidlere kıyasla daha iyi bir güvenlik profiline sahip olduğu düşünülmektedir.
Referanslar
Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, et al; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019; 114:117-127.
Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28(8):684-696.
Bubna AK. Alitretinoin in dermatology-An update. Indian J Dermatol 2015; 60:520
Cheng C, Michaels J, Scheinfeld N. Alitretinoin: A comprehensive review. Expert Opin Investig Drugs 2008; 17:437-43.
Molin S, Ruzicka T. Alitretinoin: A new treatment option for chronic refractory hand eczema. Hautarzt 2008; 59:703-9.
Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000; 1:307-14.
Schwartz RA, Micali G, Nasca RM, Scuderi L. Kaposi sarcoma: A continuing conundrum. J Am Acad Dermatol 2008; 59:179-206.
Aboulafia DM, Norris D, Henry D, Grossman RJ, Thomas J, Bundow D, et al. 9 cis retinoic acid capsules in the treatment of AIDS related Kaposi sarcoma: Results of a phase 2 multicentre clinical trial. Arch Dermatol 2003; 139:178-86.
Baumann L, Vujevich J, Halem M, Martin LK, Kerdel F, Lazarus M, et al. Open label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005; 76:69-73.
Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002; 47:969-70.
Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R; International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77-87.
Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol. 2000;136(12):1461-9.
Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002; 138:542–3.
Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol. 2006;155(4):856-7.
Luchsinger I, Vogler T, Schwieger-Briel A, Knöpfel N, Wälchli R, Weibel L, et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses- a retrospective analysis. J Eur Acad Dermatol Venereol. 2020;34(5):1037-1042.
